Patients in England diagnosed with certain types of breast cancer now have access to the drug Enhertu through the National Health Service (NHS). The medication, which is designed to treat advanced stages of the disease, has demonstrated the ability to extend life expectancy by an average of seven months.

While the drug is a new addition to the treatment options in England, it has been available to patients in Scotland for over two years. The rollout in England follows negotiations regarding the drug's cost-effectiveness and clinical utility, bringing the region into alignment with the availability already seen in other parts of the United Kingdom. Medical professionals view the inclusion of Enhertu as a significant development for patients who have limited options for managing advanced-stage breast cancer. The drug works by targeting specific proteins on cancer cells, providing a more precise approach than traditional chemotherapy. As the NHS begins prescribing the treatment, healthcare providers are expected to begin identifying patients who meet the clinical criteria for the therapy.